Author: Luo, Cheng-Xin; Wen, Zhong-Hui; Zhen, Yu; Wang, Zhu-Jun; Mu, Jing-Xi; Zhu, Min; Ouyang, Qin; Zhang, Hu
Title: Chinese research into severe ulcerative colitis has increased in quantity and complexity Document date: 2018_3_16
ID: jmjtr1pb_27
Snippet: Cyclosporine and infliximab are commonly used as salvage therapy in patients that fail to enter remission after corticosteroid treatment. Cyclosporine treatment has improved the outcome of steroids-refractory disease in SUC patients and achieved an immediate response rate of 64%-82% [2] . There is a lack of randomized controlled trials and long-term follow-up studies focused on cyclosporine treatment in China, two retrospective studies with small.....
Document: Cyclosporine and infliximab are commonly used as salvage therapy in patients that fail to enter remission after corticosteroid treatment. Cyclosporine treatment has improved the outcome of steroids-refractory disease in SUC patients and achieved an immediate response rate of 64%-82% [2] . There is a lack of randomized controlled trials and long-term follow-up studies focused on cyclosporine treatment in China, two retrospective studies with small sample size have reported a high rate of side effects. Treatment with infliximab was also reported to reduce the colectomy rate in SUC patients, but our search determined that publications on infliximab therapy in Chinese SUC patients did not appear until 2013. The 2 studies regarding infliximab treatment both reported a response rate greater than 80%, with rates of adverse effects of 17.6% and 25%. More evidence is required to evaluate the benefit and safety of both cyclosporine and infliximab treatment in Chinese SUC patients.
Search related documents:
Co phrase search for related documents- response rate and safety benefit: 1
- response rate and salvage therapy: 1, 2, 3, 4, 5, 6
- response rate and sample size: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
- response rate and small sample size: 1, 2, 3, 4, 5, 6
- response rate and steroid refractory: 1, 2, 3, 4, 5
- retrospective study and safety benefit: 1, 2
- retrospective study and salvage therapy: 1, 2, 3, 4
- retrospective study and sample size: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- retrospective study and small sample size: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50
- retrospective study and small sample size retrospective study: 1, 2, 3, 4, 5, 6, 7, 8
- retrospective study and steroid refractory: 1, 2, 3
- retrospective study and steroid refractory disease: 1
- safety benefit and salvage therapy: 1
- safety benefit and sample size: 1, 2, 3, 4, 5
- safety benefit and small sample size: 1, 2
- salvage therapy and steroid refractory: 1
- salvage therapy and steroid refractory disease: 1
- sample size and small sample size: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86
- sample size and small sample size retrospective study: 1, 2, 3, 4, 5, 6, 7, 8, 9
Co phrase search for related documents, hyperlinks ordered by date